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1. Introduction 
There is a trend towards a worldwide aging in the last decades and diseases which are 
common in the elderly people would take important place in clinical practice. Aortic 
stenosis (AS) is a common and important condition among the elderly. 
2. Etiology and prevalence 
Currently, AS is the most frequent heart valve disease in industrialized countries and its 
prevalence sharply increases with age (Iung et al., 2003; Nkomo et al., 2006). Thus with 
the prolongation of life expectancy, the population of old patients with AS is expected to 
grow in the future. In elderly patients AS is most frequently caused by progressive 
calcification and degeneration of the tricuspid aortic cusps (Otto et al., 1997; Lindroos et 
al., 1994). The comissures are not fused as in rheumatic AS. Traditionally, AS has been 
thought of as a passive degenerative ”wear and tear” disease associated with aging. 
Certain clinical factors like coronary artery disease (CAD), hypertension, obesity, 
diabetes mellitus, smoking, hyperlipidemia and chronic kidney disease (CKD) are 
associated with AS. However, the studies of Otto CM et al. support that the 
histopathological property of calcific aortic valve disease represents an active process 
with some similarities to atherosclerosis, including lipid deposition, macrophage and T 
cell infiltration, basement membrane disruption and microscopic calcification (Otto et al., 
1994). Both AS and atherosclerosis have many clinical risk factors in common such as 
diabetes mellitus, hypertension, dyslipidemia, CKD, and tobacco use. (Peltier et al., 
2003). Ortlepp JR et al observed that genetic factors may be important in the 
development of valve calcification (Ortlepp et al., 2001). They showed that patients with 
AS had significant difference in vitamin D receptor genotypes compared to individuals 
without AS. 
The research of Stewart Bf et al. revealed that in 5201 men and women older than 65 years, 
26% of study participants had frank aortic sclerosis (thickening of or calcific deposits on the 
aortic valve cusps with a peak velocity across the aortic valve of <1.5 msn) (Stewart et al., 
1997). In the initial stages, aortic sclerosis is present without stenosis, but as the disease 
advances the valve leaflets which become less mobile eventually fuse together and cause left 
ventricular outflow tract (LVOT) obstruction. The study by Cosmi JE et al., in which more 
than 2000 patients with aortic sclerosis were examined, %16 developed AS (Cosmi et al., 
2002). Of these patients mild, moderate and severe AS developed in 10.5, 3, and 2.5% 
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respectively. This cohort study showed that the average time interval of aortic sclerosis to 
AS was 8 years. 
Other causes of AS in the elderly include rheumatic aortic valve disease (always occurs 
in conjunction with mitral valve involvement) and late degeneration of congenital 
bicuspid valves (Beppu et al., 1993; Pachulski et al., 1993). Congenital bicuspid valve 
anomaly accounts for about one fourth of AS in patients older 70 than years (Passik et al., 
1987). 
3. Pathopysiology 
Regardless of the etiology, AS results in obstruction of LVOT. Obstruction of the LVOT 
leads to concentric hypertrophy (increase in LV wall thickness and mass) which normalizes 
systolic wall stress and maintains normal LV ejection fraction (LVEF) and cardiac output 
(Kennedy et al., 1968; Hood et al., 1968). Although hypertrophy helps to preserve ejection 
performance, it leads to abnormal LV compliance, LV diastolic dysfunction with reduced LV 
diastolic filling, increased LV end diastolic pressure and is associated with increased 
mortality (Levy et al., 1990; Zile et al., 2002). As the left ventricle becomes less compliant, 
atrial systole becomes more important for maintaining cardiac output, and onset of atrial 
fibrillation (AF) may result in clinical worsening and ventricular decompensation. The 
increases in systolic blood pressure, ventricular mass and ejection time lead to increased 
consumption of oxygen by the myocardium. Increased oxygen demand by the hypertrophic 
myocardium and abnormal patterns of coronary flow lead to angina pectoris in AS (Gould 
et al., 1997; Julius et al., 1997; Villari et al., 1992). Coexisting coronary disease is common 
with significant coronary narrowing in about 50% of elderly patients with AS (Georeeson et 
al., 1990). The increase in oxygen consumption and its contribution to decreased myocardial 
ischemia cause further deterioration of LV function. The stroke volume and cardiac output 
decrease and the mean left atrial and pulmonary capillary pressures increase and 
pulmonary hypertension occurs. This stage usually coincides with the occurrence of severe 
stenosis and the onset of symptoms. Several mechanisms have been postulated to explain 
the third cardinal symptom of AS, syncope. Although ventricular arrhythmias, 
bradyarrythmias and left ventricular systolic dysfunction have been proposed, most of the 
data suggests that an acute drop in blood pressure caused by inappropriate LV baroreceptor 
response because of increased LV pressures (Johnson et al., 1971; Richards et al., 1984). 
4. Natural history 
The patient with AS is generally asymptomatic for a prolonged period despite the 
obstruction and increased pressure load on the heart. Adults with asymptomatic AS have an 
excellent clinical outcome, indistinguishable from age-matched controls without aortic valve 
disease. It was estimated that sudden cardiac death accounted for 3-5% of all deaths in 
patients with asymptomatic AS (Braunwald, 1990). Hemodynamic progression in patients 
with AS has an average rate of increase in aortic jet velocity of 0.3 m/s per year, with an 
increase in mean transaortic pressure gradient of 7 mmHg per year and decrease in aortic 
valve area (AVA) of 0.1 cm2 per year (Otto et al., 1989; Faggiano et al., 1996). However there 
is a wide range of hemodynamic progression among the patients with AS. Predictors of 
symptom onset in two studies included baseline jet velocity, the rate of change in jet velocity 
over time, the extent of valvular calcification, and functional status (Otto et al., 1997; 
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Rosenhek et al., 2000). The prognosis changes dramatically with the onset of symptoms of 
angina, syncope, or heart failure (HF) after a long latent period. The development of 
symptoms is a critical point in the natural history of AS. Older adults, who typically have 
decreased activity levels, experience delayed onset of clinical symptoms or they tend to 
relate their symptoms to other coexisting conditions. Ross and Braunwald found that the 
average survival after the onset of angina pectoris, syncope and HF was 3, 3 and 1.5-2 years 
respectively (Ross & Braunwald, 1968). In the study of Bouma et al., non-operated elderly 
patients with severe AS had a wide range of survival rates (Bouma et al., 1999). In this 
study, the three poor prognostic factors were a New York Heart Association (NYHA) 
functional class of III-IV, coexisting mitral regurgitation, and left ventricular systolic 
dysfunction. Survival was particularly poor (20% at 3 years) in the presence of NYHA III-IV 
symptoms and impaired left ventricle systolic function. The presence of AS in older adults 
increases their risk of having myocardial infarction and cardiovascular death (Aronow et al., 
1998). Additional comorbidities which also affect survival are frequent in elderly patients 
with AS. 
5. Symptoms 
The cardinal manifestations of acquired AS are angina pectoris, syncope, and ultimately HF. 
Aranow et al. observed that in elderly patients, HF, syncope, or angina pectoris was present in 
90%, 69% and 27% of patients with severe, moderate and mild AS respectively (Aranow et al., 
1998). In the elderly, a clear description of the symptoms and their onset may be difficult to 
obtain. Most common initial symptom in the elderly is impaired exercise tolerance, exertional 
dyspnea and dizziness. In elderly symptoms of chest pain, shortness of breath, exercise 
intolerance, and dizziness are common and have many other potential causes, so that AS is 
generally not considered in the differential diagnosis. Symptoms may be absent in inactive 
elderly patient or may not be elicited from a patient with memory impairment. Establishment 
of symptomatic status and the severity of valvular disease can be troublesome because of 
subjectivity of symptom assessment and ambiguity of individual functional capacity in elderly 
(Sciomer et al., 2004). Concordantly, significant AS is underdiagnosed in the elderly. 
Some patients may experience severe gastrointestinal bleeding secondary to angiodysplasia 
in association with AS (Heyde Syndrome, Bhutani et al., 1995). Infective endocarditis is less 
common in elderly patients with severe AS than in younger patients because endocardial 
surface is more calcific in the elderly. Endocarditic vegetations, AF and aortic atheromas 
represent important causes of systemic embolism including stroke in the elderly patients 
(Furberg et al., 1994; Tunick et al., 1994). Rarely, fragments of the calcific valve may 
embolize into the systemic circulation. Sudden death rarely occurs in asymptomatic 
patients. In the presurgical era, the incidence of sudden death in patients with symptomatic 
AS was estimated to be as high as 15-20% (Ross, 1968). Nowadays these rates decreased due 
to early surgical intervention in patients with symptomatic AS.  
6. Signs 
AS is often diagnosed after a systolic murmur elicited on physical examination necessitates 
an echocardiogaphic examination. Signs of AS include systolic ejection cresendo-
decrescendo murmur that radiates to the neck and is often accompanied by a thrill. 
However, the murmur may radiate to the apex instead of the carotidis in elderly patients 
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with AS (Gallavardin phenomenon). A prominent fourth heart sound (S4) follows atrial 
systole in patients with sinus rhythm and noncompliant left ventricle. In the elderly, S4 is 
less specific for AS, because hypertension, CAD, and other disorders which are common in 
older individuals can diminish left ventricular compliance (Lombard et al., 1987). In this 
setting, the physical examination findings of a soft murmur with an early peak, an upstroke 
of carotid impulse with normal timing, and a split second heart sound (S2) suggest that mild 
or moderate AS is present. In a prospective study, carotid upstroke delay and amplitude, 
systolic murmur grade and peak, and a single S2 predicted AS severity and clinical 
outcomes of death and symptom onset (Munt et al., 1999). On multivariate Cox regression 
analysis, the only physical examination finding which predicted the outcome was carotid 
upstroke amplitude. But most elderly patients with severe valve obstruction have only 
grade 2 or grade 3 murmur and some have an even softer murmur despite severe disease 
because of presence of concomitant HF or chronic lung disease (Lombard et al., 1987; Otto et 
al., 1997). The pulse pressure may be normal, or even wide, and the carotid upstroke may be 
rapid in the elderly with severe stenosis due to concomitant atherosclerosis of the arterial 
tree (Otto et al., 1997). So a slow rising, low amplitude carotid pulse has a relatively high 
specificity, but a low sensitivity, for the presence of severe AS in the elderly. No single 
physical examination finding or a combination of findings has both a high sensitivity and 
specificity for detection of severe AS. Older adults have an absent A2 component of the S2 
due to aortic valve leaflet calcification which predominates with increasing age. Elderly 
patients with severe AS and aortic regurgitation have an A2 component of the S2, and in this 
situation, a soft diastolic murmur of aortic regurgitation may be heard. 
7. Diagnostic tests 
7.1 Electrocardiography 
The ECG in patients with AS is not diagnostic. Findings of LVH are the most common 
findings on ECG in patients with severe AS. In the elderly patients, findings of LVH on ECG 
were seen in about two thirds of patients (Aronow et al., 1991). The voltage of the QRS 
complex may be markedly increased and ST-T wave changes which reflect chronic 
subendocardial ischemia are common. Other nonspecific signs include, left atrial 
enlargement, left axis deviation and left bundle branch block. AF can be seen at late stages 
and may otherwise suggest coexisting mitral valve disease or CAD. 
7.2 Chest radiography 
The chest radiography in AS is nonspecific. It is usually normal when AS is mild to 
moderate. Calcification the region of the aortic valve represents relevant chest radiography 
findings in the elderly, since calcific degeneration is the hallmark of AS in this age group. 
The radiographic features of compensated AS include concentric hypertrophy of the LV 
without cardiomegaly and poststenotic dilatation of the aorta. Of equal importance, the 
presence of cardiomegaly in a normotensive patient with isolated AS indicates 
decompensated AS.  
7.3 Echocardiography 
Doppler echocardiography is a cost–effective and accurate strategy to diagnose AS in the 
elderly (Otto et al., 1997). Echocardiography allows for the noninvasive assessment of the 
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valvular structures and the real time evaluation of its hemodynamic consequences. It 
assesses left-ventricular functions, extent of hypertrophy, and amount of valve 
calcification. Standard evaluation of AS severity includes measurement of aortic velocity, 
mean transaortic pressure gradient, and continuity equation valve area (Figure 1). 
Anatomic images show the etiology of AS, level of obstruction, valve calcification, leaflet 
motion and aortic root anatomy. Echocardiography is also used to determine diastolic 
dysfunction by the presence of abnormal left ventricular relaxation. The velocity of blood 
flow increases as the stenotic orifice area decreases. Velocity measurements can be 
translated into pressure gradients across the aortic valve by using the Bernoulli equation. 
Aortic velocity allows classification of stenosis as mild (2.6-3 m/s), moderate (3 to 4 
m/s), or severe (>4m/s). In case of leaflet thickening and calcification, presence of 
adequate leaflet motion and a velocity of <2.5 m/s defines aortic sclerosis. A mean aortic 




Fig. 1. To obtain the mean gradient, "trace" is used to trace the envelope of the aortic 
outflow. A mean aortic valve gradient greater than 40 mm Hg on Doppler 
echocardiography is indicative of severe AS. 
The AVA can be estimated with the use of the continuity equation which depends on the 
principle of the law of continuity of flow (Carabello et al., 2003). Currently AS is graded as 
mild, moderate, and severe when the AVA is >1.5 cm2, 1-1.5 cm2, and <1 cm2 respectively 
(Table 1). The most frequent error in measuring the AVA is due to the inaccuracy of LVOT 
diameter measurement. This is especially difficult in older adults in whom accumulation of 
calcium is present on the annulus. In order to avoid these errors some authorities suggest 
the use of dimensionless ratio for the assessment of AS. This index is simply the ratio of the 
velocity across the LVOT to the velocity across the aortic valve and completely eliminates 
the area of the LVOT from the equation (Otto et al., 2006). A ratio of 0.9-1 is accepted normal 
and a ratio of <0.25 indicates a valve area 25% of expected, corresponding to severe stenosis. 
Transesophageal echocardiography provides excellent short-axis images of the aortic valve, 
thus allows for direct measurement of the AVA by planimetry in many patients (Naqvi et 
al., 1999). Real time three dimensional transthoracic echocardiography offers an increased 
www.intechopen.com
  
Aortic Valve Stenosis – Current View on Diagnostics and Treatment 
 
40
confidence level in the direct measurement of AVA (Vengala et al., 2004). Dobutamine stress 
echocardiography is often useful to estimate AVA and gradient at a higher cardiac output. It 
is particularly useful in patients with moderate to severe AS with low gradient and 
depressed LVEF. Truly severe AS shows only small changes (an increase of <0.2 cm2) in 
AVA which remains <1 cm2 with increasing flow rate but significant increase in gradients 
(mean gradient > 40 mmHg), whereas pseudosevere AS shows a marked increase in AVA 
with a final value of > 1 cm2 but only minor changes in gradients. Dobutamine stress 
echocardiography also provides evidence of myocardial contractile reserve (increase of 
>20% of stroke volume during low dose dobutamine administration) (Vahanian et al., 2007; 
Bonow et al., 2006). Echocardiography is recommended to be performed yearly in patients 
with severe AS, every 2 years in patients with moderate AS, and every 5 years in patients 
with mild AS. 
 
 Mild Moderate Severe 
AoVmax (m/s) 2.5-3.0 3.0-4.0 >4.0 
Peak gradient 
(mmHg) 
<40 40-65 >65 
Mean gradient 
(mmHg) 
<20 20-40 (50)*  >40 (50)* 
EOA (cont eq) (cm2) >1.5 1.0-1.5 <1.0 
EOAi (cm2/ m2) >0.85 0.60-0.85 <0.60 
Dimensionless index  >0.50 0.25-0.50 <0.25 
Table 1. Grading of aortic stenosis. *EAE guidelines only, otherwise both EAE and ASE. 
7.4 Exercise testing 
Severe AS is considered a contraindication for exercise testing (Ha, 2003). Nonetheless, in 
elderly patients with hemodynamically significant AS and ambiguous symptoms, exercise 
testing may be useful and safe if performed by an experienced physician. It is reasonable to 
perform the exercise testing it in patients over 70 years if they are still highly active. In 
asymptomatic patients, this test also may determine the recommended level of physical 
activity. 
7.5 Cardiac catheterization 
Its principle goal is to asses the extent of concomitant CAD (which is common in the elderly) 
by angiography rather than to determine the hemodynamic severity of AS. The valve should 
almost never be crossed, because the risk of death, stroke, or pulmonary edema is 7% if the 
valve is crossed and 3% for coronary angiography (Chambes, 2004). If the clinical findings 
are not consistent with the Doppler echocardiographic results, cardiac catheterization is 
recommended for further hemodynamic assessment. Cardiac catheterization should consist 
of the simultaneous measurement of the pressures in the left ventricle and in the aorta, 
enabling the calculation of the mean gradient. A ‘’pull-back’’ tracing from the left ventricle 
to the aorta may be used in patients with normal sinus rhythm but it is not accurate in 
patients with rhythms disturbances or low-output states. In elderly patients with tortuous 
vessels the pull back technique may be preferred to a second femoral puncture needed to 
obtain a proper LV and proximal aortic pressure recording. 
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7.6 Computer tomography (CT) 
Electron beam CT has the ability to detect and quantify calcification in AS (Pohle, 2004). It 
also allows detection of calcifications in coronary vessels and assessment of the ascending 
aorta (Pohle et al., 2004; Bouma et al., 1999). CT has shown high accuracy and 
reproducibility in quantifying aortic valve calcification and its progression. In patients 
with inadequate and inconclusive echocardiogram, CT may be as an alternative to obtain 
AVA. 
7.7 Magnetic Resonance Imaging (MRI) 
Cardiac MRI may be used to assess LV volume, function and mass. MR planimetry is 
reported to be highly reproducible and well tolerated and the results correlate very well 
with TEE results (Anna et al., 2003). Cardiac MRI is useful when acoustic windows in the 
echocardiogram are poor or when there is discordant imaging and catheterization 
results. It may also be an alternative to CT in patients with increased risk of contrast 
nephropathy because of older age and diminished baseline glomerular filtration rate 
(GFR). 
8. Medical treatment 
When symptoms of angina, syncope, or HF develop in patients with AS, the prognosis 
dramatically worsens. AVR represents the only proven treatment modality for 
symptomatic and hemodynamically significant AS. Other treatments such as medical 
therapy and TAVI are still controversial and researches are on way. There is no effective 
medical treatment for AS. Although medical therapy is unlikely to prolong survival, it 
may provide limited symptomatic relief. Hemodynamically significant AS is adversely 
affected by changes in preload and afterload. Potentially, all drugs used in symptomatic 
patients may cause worsening of the patients’ conditions. Therefore, in patients with 
severe AS, drugs that reduce preload or afterload should be used with caution. In 
addition, due to the fact that chronic renal failure, autonomic dysfunction, and rhythm 
and conduction disturbances are more frequently seen in the elderly, side effects of drugs 
may be more dangerous. 
8.1 Statins 
Lipids are known to have important role in development of fibrosis and calcification seen in 
AS. Therefore, the use of lipid lowering drugs, especially the statins are recommended. 
Various studies suggested that the use of statins may reduce or prevent the worsening of 
fibrosis and calcification in patients with AS especially when used in the early periods. 
However, the results of the studies are conflicting and the effects of statins on the course of 
disease are not clear. Findings of several retrospective studies and at least one prospective 
trial show that patients receiving statins have slower progression of stenosis severity than 
do individuals not receiving them.(Rajamannan & Otto, 2004; Novaro et al., 2001). However, 
in a randomized trial of patients with moderate AS, Cowell and colleagues failed to show a 
benefit of high dose statin use in terms of halting the progression of valvular stenosis or 
inducing its regression (Cowell et al., 2005). Although the use of statins in patients with 
valvular AS is controversial, statins should be used in patients with AS and atherosclerotic 
vascular disease (Rossebø et al., 2008). 
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8.2 Angiotensin converting enzyme inhibitors (ACEI) 
When patients with severe AS who can not tolerate AVR develop left HF symptoms, the use 
of ACEI may provide improvement in symptoms. Similar to statins, ACEI have been 
suggested to slow the progression of calcific valvular stenosis, but this suggestion has not 
been confirmed by findings of prospective studies (Rosenhek et al., 2004). On the other 
hand, the use of ACEI in patients with severe AS may increase the transvalvular gradient by 
reducing afterload or preload and may cause sudden deterioration of the patients’ status. 
ACEI treatment should be initiated at low doses and gradually increased, avoidance of 
hypotension is crucial especially in the elderly patients. 
8.3 Beta blockers 
Beta blockers are not recommended for routine use. Patients with symptoms and signs of 
HF are not good candidates for beta blocker treatment because beta blockers may aggravate 
the symptoms of HF. Beta blockers are recommended for patients who experience angina 
pectoris or have AF with rapid ventricular response. 
8.4 Diuretics 
Diuretics are recommended in patients with lung congestion, ascites and edema. Diuretics 
provide improvement in HF symptoms by reducing left ventricular end-diastolic pressure. 
Diuretics should be used with caution because a low preload may exacerbate symptoms due 
to low cardiac output. Elderly patients may not excrete free water as efficiently as younger 
people do, and they may be more prone to develop hyponatremia after diuretic treatment 
(Clark et al., 1994). Thiazide diuretics are more commonly associated with hyponatremia 
than loop diuretics (Hwang & Kim, 2010). Nocturia is frequently seen in elderly patients and 
disruption of normal circadian rhythm of antidiuretic hormone may be an important factor 
in this issue (Moon et al., 2004). Elderly patients are also more prone to diuretic induced 
hyponatremia, because concomitant use of other medications like selective serotonin 
reuptake inhibitors (SSRI), which may precipitate hyponatremia, is common. Diuretics also 
lead to orthostatic hypotension by inducing volume depletion. Because falls are more 
frequent and are associated with greater morbidity and mortality in the elderly patients, 
monitoring of blood pressure at home and avoidance of hypotension is crucial. Evening and 
night doses of diuretics are also associated with more frequent nocturia and may increase 
the risk of falls during night. Thus, administration of diuretics in earlier hours may be safer. 
8.5 Nitrates 
Nitrates may be used in patients with severe AS who experience angina pectoris. Because it 
may cause sudden hypotension, it should be initiated at low doses and gradually increased. 
Concomitant use of nitrates with phosphodiesterase inhibitors, which are commonly used in 
the elderly patients with erectile dysfunction, should be avoided to prevent substantial 
hypotension. 
8.6 Digoxin 
Digoxin has a narrow therapeutic index and elderly patients may be more prone to side 
effects associated with its use (Cheng & Nayar, 2009). Digoxin is eliminated by the kidneys 
and impairment of kidney functions with aging is an important issue in this context. The 
recent ACC/AHA guideline recommends an initial dose of 0.125 mg daily or every other 
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day if the patient is more than 70 years old, has impaired kidney function, or has a low lean 
body mass (Hunt et al., 2009). Using a target drug concentration of 0.5-1 ng/ml is 
recommended despite conventional therapeutic serum concentration is defined as 0.8-2 
ng/ml (Hunt et al., 2009). A digoxin concentration above 1 ng/ml may not be more effective 
in terms of symptomatic relief and may potentially be associated with increased morbidity 
and mortality (Cheng & Nayar, 2009; Hunt et al., 2009). When hypokalemia, 
hypomagnesemia or hypothyroidism coexists, digoxin toxicity may occur with lower 
digoxin concentrations (Hunt et al., 2009). Elderly patients may also be more prone to 
develop adverse effects of digoxin like anorexia, nausea, vomiting, confusion, visual 
problems, and rhythm and conduction disturbances (Cheng & Nayar, 2009). Concomitant 
use of drugs which may interact with digoxin may also be common in the elderly. In this 
context, clarithromycin, erythromycin, amiodarone, itraconazole, cyclosporine, verapamil, 
and quinidine can increase serum digoxin concentrations (Hunt et al., 2009). The use of 
digoxin is contraindicated in patients with severe AS and sinus rhythm. When AF with 
rapid ventricular response and hemodynamic deterioration is present, digoxin may be used 
to reduce the ventricular rate. Because beta blockers improve survival in patients with HF 
and may effectively control heart rate alone, digoxin which is associated with 
aforementioned potential harms, should be used with caution as an adjunctive agent for 
heart rate control. 
9. Perioperative evaluation and management 
9.1 Evaluation and management 
Decision to identify patients who are at high risk for cardiac surgery is cumbersome. This 
issue may be further complicated in the elderly. Some risk score algorithms like Ambler 
score, logistic EuroSCORE and Society of Thoracic Surgeons Predicted Risk of Mortality 
(STS-PROM) are widely used to identify patients at high risk for cardiac surgery. Ambler 
score was dedicated to predict in-hospital mortality after heart valve surgery (Ambler et al., 
2005). EuroSCORE integrates increased age, female gender, chronic pulmonary disease, 
extracardiac arteriopathy, neurological dysfunction, previous cardiac surgery, increased 
serum creatinine, active endocarditis, critical perioperative state, unstable angina, LV 
dysfunction, recent MI, and pulmonary hypertension as patient and cardiac related factors 
and some operation related factors like emergency, other than isolated CABG, surgery on 
thoracic aorta, and postinfarct septal rupture (Nashef et al., 1999). An online calculator is 
available in their official website (http://www.euroscore.org/). The STS-PROM risk scoring 
which is more complicated integrates age, gender, race, weight, creatinine level, various 
chronic cardiac and non-cardiac diseases, previous cardiovascular interventions, 
perioperative cardiac status, hemodynamic status, and operative risk factors. This scoring 
estimates the rates of postoperative morbidity, mortality, permanent stroke, prolonged 
ventilation, renal failure, and reoperation. It is updated regularly and calculation can be 
performed only via the online calculator (http://www.sts.org/). Recent data indicates that 
these scores may also predict hospital charges and resource use (Arnaoutakis et al., 2011). 
These risk score algorithms are widely used and validated, but they are not perfect and have 
many limitations (Rosenhek et al., 2011). Elderly patients above 75 years old constituted a 
small proportion of the cohorts used in these risk scores, thus extrapolation of these results 
to frail elderly patients who are generally above 75 years old may not give accurate results. 
In this context, a recent study which involved 1245 elderly patients (mean age 77.2 years) 
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who underwent AVR with or without additional bypass surgery, suggested that among 
these three risk scores, only STS-PROM was correlated with operative mortality (Frilling et 
al., 2010). The authors emphasized that risk scores aimed specifically at geriatric patients 
might be necessary to accurately identify patients with high surgical risk. These scores have 
mainly been validated in patients undergoing CABG surgery, compromising their accuracy 
in patients undergoing heart valve replacement surgery (Rosenhek et al., 2011). 
Comorbidities not included in these algorithms may increase the risk of surgery. Rosenhek 
et al suggest necessity of including additional variables like cognitive and functional 
capacity to the risk assessment tools (Rosenhek et al., 2011). Moreover, the weighting of the 
risk factors are variable between these algorithms. For example, EuroSCORE includes a 
cutoff point for creatinine (200 μmol/L), which means a creatinine level above this level 
increases the risk, whereas a lower level does not increase the risk. This suggestion has two 
limitations. First, a creatinine level above this threshold in a 65 year old male who weights 
90 kg may suggest a better renal function than a creatinine level below this level in an 85 
year old female who weights 50 kg. Furthermore, the creatinine level may not reflect 
glomerular filtration rate (GFR) accurately in a slim and sarcopenic elderly patient. 
Pulmonary arterial systolic pressure is also categorized in a binary fashion, thus decreasing 
the value of this important risk factor in this scoring system. STS-PROM does not use a 
cutoff for creatinine level and utilizes creatinine level as a continuous variable. However, the 
muscle mass is an important determinant of creatinine levels. A low muscle mass may 
actually represent a poor prognostic factor while it would be associated with a lower 
creatinine level, thus decreasing the STS-PROM risk score. Using more accurate estimations 
of GFR like Cockcroft-Gault formula may give more important prognostic information. 
Cystatin C which is not influenced by muscle mass may potentially reflect GFR more 
accurately and its level increase in earlier stages of kidney insufficiency compared to 
creatinine. However, there are limitations with measurement techniques of cystatin C and 
estimation of GFR by cystatin C levels is not standardized because there are many cystatin C 
based formulas to estimate GFR. The physiologic changes associated with aging should 
always be considered. A comprehensive geriatric assessment would also provide invaluable 
information in the preoperative evaluation and postoperative follow up of the elderly 
patients. 
Morbidity and mortality rates may also be influenced by other factors like experience of 
the surgeon and the center (Rosenhek et al., 2011). Thus it would be logical to compare 
local outcomes with those predicted by the risk scores. Nonetheless, the decision of an 
experienced physician or of a specialized team may be more accurate than the risk scores. 
A recent trial which utilized STS-PROM, presence of pulmonary hypertension, presence 
of porcelain aorta and the decision of the medical team that the patient is frail as the 
criteria to decide a patient is inoperable and to enroll them to TAVI procedures (Rodés-
Cabau el al., 2010). They suggested that frail patients even with a low STS-PROM score 
had increased risk. Although the decision of an experienced medical team that a patient is 
frail may be accurate, usage of widely used criteria to identify frailty may be more 
accurate and enable utilization of frailty as a risk factor in the preoperative evaluation in a 
standardized manner. 
Brain natriuretic peptide (BNP) is widely used for prognostic prediction in heart diseases. 
BNP is higher in symptomatic patients compared to asymptomatic patients (Carabello & 
Paulus, 2009). BNP may also predict onset of symptoms when elevated values are found in 
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an asymptomatic patient and facilitate advising surgery to an asymptomatic patient with AS 
(Carabello & Paulus, 2009). Recently Monin et al. followed up 107 asymptomatic patients 
with moderate to severe AS to predict death or need for AVR and to build a continuous risk 
score using the independent predictors of this outcome (Monin et al., 2009). One of the most 
powerful predictors of outcome was BNP in this study. BNP levels were shown to predict 
postoperative survival and complications (Bergler-Klein et al., 2004; Nozohoor el al., 2009; 
Pedrazzini et al., 2008). Limitations of utilizing BNP include absence of a standardized 
cutoff for prediction of outcome in AS, interference of the predictive value of BNP with 
presence of renal dysfunction, pulmonary hypertension and obesity (Carabello & Paulus, 
2009). Unlike BNP, amino terminal-proBNP levels may increase significantly when renal 
dysfunction exists, thus it seems more suitable to use BNP levels in patients with renal 
dysfunction (Tagore et al., 2008). Bernstein et al. suggest adjustment of proBNP levels with a 
formula utilizing estimated GFR level and age (Bernstein et al., 2009). 
Sündermann at al utilized a comprehensive assessment of frailty (CAF) score to predict 
outcomes after cardiac interventions (CABG, valve surgery, TAVI or combined procedures) 
in 400 patients aged ≥74 years (Sündermann at al., 2011). This score integrated weakness 
assessed with grip strength, self-reported exhaustion assessed with a questionnaire, 
slowness of gait speed measured with 4 meter usual gait speed test, activity level evaluated 
by instrumental activities of daily living, standing balance, body control, forced expiratory 
volume in 1 s, and levels of albumin, creatinine, and BNP. Although the variables were used 
in a binary fashion in this study CAF score was found to be correlated with EuroSCORE and 
STS-PROM scores and also predicted 30-day mortality. 
A recent study which investigated influence of preoperative LV diastolic functions on 
development of postoperative LV systolic dysfunction showed that besides advanced age 
and prolonged myocardial ischemic time, preoperative LV diastolic dysfunction was also an 
important determinant of LV systolic dysfunction after AVR operation (Licker et al., 2010). 
Another recent study assessed presence and degree of myocardial fibrosis on the outcomes 
after AVR (Weidemann et al., 2009). Intraoperative myocardial biopsy and preoperative and 
postoperative cardiac MRI were used to assess myocardial fibrosis in this study. They found 
a significant correlation of myocardial fibrosis with NHYA class and markers of 
longitudinal systolic function but not with global ejection fraction or aortic valve area. They 
found significant correlations between the presence and degree of myocardial fibrosis and 
clinical outcomes. Another recent study evaluated the influence of preoperative illness 
beliefs on postoperative disability, physical functioning, psychological well being and 
depressive symptoms (Juergens et al., 2010). Postoperative outcomes were correlated with 
patients’ preoperative beliefs but not with cardiac risk factors used in this study 
(EuroSCORE and LVEF). 
Spirometric pulmonary functions were assessed preoperatively in a recent trial and 
percentage of predictive forced vital capacity was found to be an independent predictor of 
in-hospital mortality, even when adjusted for the logistic EuroSCORE (Nissinen et al., 2009). 
They also suggested that this parameter was an independent predictor of postoperative 
stroke. 
Preoperative six minute walk test with a cutoff value of 300 meters was utilized in patients 
undergoing AVR in a recent trial (de Arenaza et al., 2010). It was indicated that six minute 
walk test added prognostic information to EuroSCORE and was an independent predictor 
of the composite outcome of death, myocardial infarction or stroke at 12 months. 
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Monin et al suggested that a good outcome after AVR may be seen when severe AS caused 
left-ventricular dysfunction, especially if inotropic reserve is present (Monin et al., 2003). 
They utilized dobutamine stress Doppler hemodynamics to show presence of LV contractile 
reserve in their study. 
Aside from a high risk score, there are some other factors like patient refusal and porcelain 
aorta which deem some of the patients inoperable. The opinion of the experienced physician 
is also important to define patients at higher risk for surgery and to provide required 
precautions for the patients. Furthermore there are more non-invasive procedures like TAVI 
which may be used in patients with a high surgical risk. 
Current ESC and ACC/AHA guidelines were published in 2007 and 2008 respectively. ESC 
guidelines emphasize that AS is increasingly observed in the elderly and AVR could 
prolong and improve the quality of life despite the increased risks of morbidity and 
mortality in this population (Vahanian et al., 2007). It is also noticed that a large percentage 
of suitable candidates for AVR are not referred for surgery. It is recommended that age, per 
se, should not be considered a contraindication for surgery and decisions should be made 
on an individual basis, provided that patients’ wishes and cardiac and non-cardiac factors 
are taken into account. It is also denoted that early intervention at an asymptomatic stage 
should be avoided. ACC/AHA guidelines state that no effective medical treatment exists 
and balloon valvotomy is not a suitable alternative to surgery (Bonow et al., 2008). Among 
denotations about valve surgery in elderly patients in these guidelines are: CAD and LV 
dysfunction are associated with worse outcomes; advanced diseases like cancer, stroke and 
dementia render surgery inappropriate; and deconditioned and debilitated patients often do 
not return to an active life after surgery. Other peculiar considerations stated for the elderly 
are: a narrow LVOT and a small aortic annulus could require enlargement of the annulus, 
heavy calcification may require debridement, and a composite valve-aortic graft may be 
needed. Importance of recognition of marked LV hypertrophy which could be a marker of 
perioperative morbidity and mortality is emphasized. Absence of a perfect method to weigh 
all of the relevant factors and to identify high- and low-risk elderly is also noted.  
Data about comparison of mechanical prostheses and bioprostheses for AVR in the elderly is 
scarce. One recent report suggests good outcomes of bioprostheses for AVR after more than 
10 years of follow up in the elderly (Suojaranta-Ylinen et al., 2009). In the Veterans Affairs 
randomized trial, patients who underwent single AVR or mitral valve replacement with 
mechanical valve versus bioprosthesis were enrolled in a randomized fashion 
(Hammermeister et al., 2000). They found a better survival with mechanical valves largely 
because primary valve failure was virtually absent in this the mechanical valve group while 
it was seen in an important proportion of the bioprosthesis group. However primary valve 
failure was not significantly different between these groups in the elderly population. While 
the rate of thromboembolism was similar between the groups, bleeding complications were 
more common in the mechanical valve group. It is of note that lifelong warfarin treatment is 
required in patients who undergo AVR with mechanical valves and bleeding complications 
with warfarin is more common in the elderly. Further trials are needed to compare the 
outcomes of AVR with mechanical valves and bioprostheses in the elderly. 
Patients with severe AS may have markedly reduced platelet functions and thus experience 
increased postoperative blood loss. One recent double-blind placebo controlled trial 
investigated effects of infusion of desmopressin (0.3 μg/kg) on platelet functions and 
postoperative blood loss (Steinlechner et al., 2011). They recommended assessing of platelet 
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functions and usage of desmopressin to avoid increased blood loss in patients with reduced 
platelet functions. 
Among perioperative cautions for the patient with AS, careful manipulation of 
hemodynamics is crucial (Frogel & Galusca, 2010). Main goals to decrease the perioperative 
cardiovascular risk are to maintain sinus rhythm, a relatively slow heart rate, and adequate 
preload and afterload (Frogel & Galusca, 2010). In this context, a slower heart rate decreases 
myocardial oxygen demand and increases coronary perfusion time. Routine antibiotic 
prophylaxis is not recommended unless the patient has a previous history of infective 
endocarditis (Frogel & Galusca, 2010). Regarding anesthetic premedication, anticholinergics 
may cause tachycardia in a dose dependent manner and careful titration of sedation is 
crucial because oversedation may cause hypotension and undersedation may increase the 
sympathetic tone (Frogel & Galusca, 2010). Because of the risk of serious arrhythmias, a 
defibrillator should be readily available and placed on the patient before sterile draping. 
Ideal heart rate is in the range of 60 to 70 beats per minute and bradicardia should be 
avoided especially in the elderly patients who may have predisposition to it (Frogel & 
Galusca, 2010). As atrial systole is necessary for maximal LV preload, maintenance of 
normal sinus rhythm is very important. Adequate hydration is very important as well, since 
patients with AS are preload dependent (Frogel & Galusca, 2010). Elderly patients and 
patients with central nervous system disorders affecting sensation of thirst have tendency to 
develop dehydration and need careful evaluation of hydration status. Regarding type of 
anesthesia, an epidural technique may be preferred to neuroaxial anesthesia with 
sympathectomy because it allows incremental dosing and does not cause sudden changes in 
systemic vascular resistance (Frogel & Galusca, 2010). Opioids, midazolam, etomidate and 
cisatracurium may be good options for general anesthesia because they offer relatively 
stable hemodynamic effects (Frogel & Galusca, 2010). Careful monitoring of the blood 
pressure is pivotal and hypotension should be avoided and once hypotension develops it 
should be controlled with pure α agonists since they do not cause tachycardia (Frogel & 
Galusca, 2010). Invasive arterial blood pressure and central venous pressure monitoring are 
also recommended. 
Elderly patients are at increased risk for experiencing adverse events like delirium and 
electrolyte disorders in the postoperative period. There are many metabolic, infectious and 
psychological factors which predispose the frail elderly to develop delirium. It is of note that 
delirium is very common after cardiac surgery and is associated with increased risk of short 
and long term morbidity and mortality (Maldonado et al., 2009). Psychotic symptoms of 
delirium like hallucinations and delusions are easily recognized, but many patients do not 
have these symptoms and routine assessment of attention and orientation is crucial. Of note, 
symptoms of delirium wax and wane and make identification of it difficult. Despite its high 
prevalence and adverse outcomes, many physicians do not recognize delirium (Maldonado 
et al., 2009). Giltay et al., focused on the psychotic symptoms of delirium after cardiac 
surgery and suggested that they are independently associated with adverse outcomes 
(Giltay et al., 2006). They found higher age, renal failure, dyspnea, HF, and left ventricle 
hypertrophy as independent preoperative predisposing factors and hypothermia (<33,8°C), 
hypoxemia, low hematocrit, renal failure, increased sodium, infection and stroke as 
independent precipitating factors. Careful monitorization of volume status, follow up of 
renal functions and electrolyte levels, adequate pain control and rational medication 
selection are of great importance. Many drugs like anticholinergics, antihistaminics, 
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narcotics and central acting drugs like benzodiazepines may precipitate delirium in an 
elderly patient with predisposing factors. When a precipitating factor for delirium is 
identified in a delirious patient, search of other potential causes of it should continue, 
because especially patients without dementia do not easily develop delirium. Maldonado et 
al. investigated the effects of postoperative sedation on the development of delirium in 
patients undergoing cardiac valve surgery (Maldonado et al., 2009). They compared 
dexmedetomidine, which is not a GABAergic agent, has no anticholinergic effects, promotes 
a more physiological sleep pattern without significant respiratory depression, and may be 
associated with a decreased need for opioid use, with current postoperative sedation 
practices (propofol or midazolam) in a prospective, randomized and open label trial. They 
showed a significantly decreased rate of delirium with dexmedetomidine compared to 
propofol and midazolam (rates of delirium 3%, 50% and 50% respectively). 
Because fluid and electrolyte disturbances are common in the elderly, especially in the 
postoperative period, avoidance of hypotonic fluid administration and monitorization of 
volume status and electrolytes are crucial. 
9.2 Perioperative management for noncardiac surgery in patients with aortic stenosis 
Regarding noncardiac operations, postponing elective surgery is recommended for patients 
with symptomatic severe AS or asymptomatic severe AS in whom evaluation of the valve 
has not been done within the last year (Fleisher et al., 2009). If AVR is not feasible because of 
comorbidities or patient refusal, mortality risk of noncardiac surgery is approximately 10% 
in patients with severe AS (Fleisher et al., 2009). Stratification of cardiac risk for noncardiac 
surgery reported in the current ACC/AHA guidelines is summarized in Table 2 (Fleisher et 
al., 2009). In patients with mild or moderate AS, no clear recommendation is present (Bonow 
et al., 2008). In the asymptomatic patient with severe AS, AVR is indicated if concurrent 
CABG operation is required; if EF is below 50%; or if likelihood of rapid progression is high 
(Bonow et al., 2008). If symptoms are equivocal, an exercise test can be performed and AVR 
may be planned if symptoms or hypotension occur during the test. Beta blocker treatment 
should be continued if class I indications for it exist. If the patient is not using beta blockers 
and has CAD or more than one cardiac risk factor, titration of beta blockers to heart rate and 
blood pressure is recommended if the patient will undergo high- or intermediate-risk 
surgery (Fleisher et al., 2009). These cardiac risk factors are listed in Table 3. Starting beta 
blocker treatment in low doses and careful titration is important in elderly patients who are 
at increased risk for bradycardia and hypotension and thus adverse events like falls. 
Furthermore, data about the role of beta blockers in intermediate- and low-risk patients and 
optimal type, dose, timing, duration, and titration of beta blockers are lacking (Fleisher et 
al., 2009). Withdrawal of beta blockers in the preoperative period is associated with adverse 
outcomes and should not be done unless necessary. Cessation of metformin and renin 
angiotensin system blockers, which increase the risk of postoperative lactic acidosis and 
renal insufficiency respectively, before the surgical procedure is essential. In a recent study 
by Calleja et al., elderly patients with asymptomatic severe AS had low morbidity rates that 
were similar to that seen in well-matched patients with mild-to-moderate AS following 
intermediate-to-low-risk noncardiac surgery (Calleja et al., 2010). No postoperative death or 
HF was observed until dismissal. However, intraoperative hypotension requiring 
vasopressor use was more common in patients with asymptomatic severe AS. BNP may also 
be used to predict postoperative poor outcomes in patients with heart disease undergoing 
noncardiac surgery, however data about BNP used for this purpose is scarce. Leibowitz et 
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al. suggest that it may be beneficial to measure BNP levels in the preoperative period for this 
purpose (Leibowitz et al., 2008). 
 
Risk Stratification Procedure Examples 
Vascular (reported CR often 
more than 5%) 
Aortic and other major vascular surgery 
Peripheral vascular surgery 
Intermediate (reported CR 
generally 1% to 5%) 
Intraperitoneal and intrathoracic surgery 
Carotid endarterectomy 
Head and neck surgery 
Orthopedic surgery 
Prostate surgery 
Low (reported CR generally 






* Combined incidence of cardiac death and nonfatal myocardial infarction. CR: cardiac risk. 
Table 2. Cardiac Risk* Stratification for Noncardiac Surgical Procedures 
 
History of ischemic heart disease 
History of compensated or prior heart failure 
History of cerebrovascular disease 
Diabetes Mellitus 
Renal insufficiency (defined as a preoperative serum creatinine of greater than 2 mg/dL). 
Table 3. Clinical risk factors for perioperative cardiovascular complications 
10. Surgery 
Approximately 2% to 5% of elderly individuals aged 75 years present with signs of severe 
AS and they are scheduled for elective AVR. AVR is the treatment of choice for patients with 
severe degenerative AS, offering both symptomatic relief and a potential for improved long-
term survival (Heinze et al., 2010). The results of the conventional surgery for octogenarians 
are satisfactory and 5% to 10% of mortality is noted for isolated AVR (Heinze et al., 2010). 
On the other hand, elderly patients stay longer in the hospitals and intensive care units 
during the postoperative period (Avery et al., 2001). 
In 1912, Theodore Tuffier was the first to attempt opening AS using his finger. Russel Brock 
and then Bailey used dilatators for stenotic aortic valves. Today more than 1000 patients 
have aortic valve surgery per year and surgery for AS is more common than it is for aortic 
insufficiency. (Barbour J.R. & Ikonımidis J.S., 2007). It’s obvious that AVR is indicated in all 
symptomatic patients and asymptomatic patients with severe AS undergoing open heart 
surgery. The surgery should immediately be programmed if the patient becomes 
symptomatic. United Kingdom heart valve registry observed 1100 elderly patients (56% 
women) who underwent AVR and the 30-day mortality was 6.6% (Asimakopoulos, 1997, as 
cited in Aronow, 2007). The actuarial survival was 89% at 1 year, 79% at 3 years, 69% at 5 
years, and 46% at 8 years. The mortality is rising up to 10% per year for the patient who 
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becomes symptomatic. The indications for AVR in patients with AS according to the current 
ACC/AHA guidelines are listed in Table 4 (Bonow et al., 2006). 
 
Class I  
AVR is indicated for symptomatic patients with severe AS.* (Level of Evidence: B)  
AVR is indicated for patients with severe AS* undergoing coronary artery bypass graft 
surgery (CABG). (Level of Evidence: C)  
AVR is indicated for patients with severe AS* undergoing surgery on the aorta or other 
heart valves. (Level of Evidence: C)  
AVR is recommended for patients with severe AS* and LV systolic dysfunction (ejection 
fraction less than 0.50). (Level of Evidence: C)  
Class IIa  
AVR is reasonable for patients with moderate AS* undergoing CABG or surgery on the 
aorta or other heart valves (see Section 3.7 on combined multiple valve disease and 
Section 10.4 on AVR in patients undergoing CABG). (Level of Evidence: B)  
Class IIb  
AVR may be considered for asymptomatic patients with severe AS* and abnormal 
response to exercise (e.g., development of symptoms or asymptomatic hypotension). 
(Level of Evidence: C)  
AVR may be considered for adults with severe asymptomatic AS* if there is a high 
likelihood of rapid progression (age, calcification, and CAD) or if surgery might be 
delayed at the time of symptom onset. (Level of Evidence: C)  
AVR may be considered in patients undergoing CABG who have mild AS* when there is 
evidence, such as moderate to severe valve calcification, that progression may be rapid. 
(Level of Evidence: C)  
AVR may be considered for asymptomatic patients with extremely severe AS (aortic valve 
area less than 0.6 cm2, mean gradient greater than 60 mm Hg, and jet velocity greater than 
5.0 m per second) when the patient’s expected operative mortality is 1.0% or less. (Level of 
Evidence: C)  
Class III  
AVR is not useful for the prevention of sudden death in asymptomatic patients with AS 
who have none of the findings listed under the class IIa/IIb recommendations. (Level of 
Evidence: B)  
Table 4. Indications for Aortic Valve Replacement.  
Although the surgery for the asymptomatic patients is preferred due to risk of sudden death, 
surgery for asymptomatic octogenarians is controversial. The complex cardiac procedures 
have high risks for elderly patients. The mortality rate of valve surgery and risk of sudden 
death without surgery have to be carefully considered. Postoperatively symptoms diminish 
and quality of life is improved in the majority of patients ≥75 years who had undergone aortic 
valve surgery, but long term survival was not affected (Petersen & Poulsen, 2010). 
AVR usually performed under general anesthesia using conventional techniques of open-
heart surgery with median sternotomy. Minimally invasive procedures are associated with 
acceptable mortality and morbidity rates even in high risk patients. Minimally invasive 
aortic valve surgery can be performed through three different approaches. These are upper 
mini sternotomy, transverse sternotomy and right parasternal mini thoracotomy, sometimes 
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using port-access technique. This procedure has advantages such as less surgical trauma, 
decreased pain and faster recovery. Small incisions may also be associated with low 
infection rates (Olin et al., 1999). It reduces blood transfusions and shortens the length of 
hospital and ICU stay (Korach et al., 2010). It is a safe operation and is associated with lower 
incidence of atelectasis in the cardiac ICU (Foghsgaard et al., 2009). Port access aortic 
surgery also allows patients to be extubated earlier (Wheatley et al., 2004). Avoidance of full 
sternotomy for osteoporotic elderly patients prompts a comfortable postoperative period.  
Although the number of the aortic valve procedures increase worldwide, the ideal valve 
choice is still a debate. There are several options for valves. These are mechanical valve 
prostheses, stented and stentless bioprosthetic valves, aortic homografts and pulmonary 
autografts. The use of these valves differs from patient to patient due to comorbidities and 
anticoagulant needs. The bioprosthetic valves are good alternatives for elderly patients 
because long term anticoagulation use is not required. 
The other situation for the elderly patients undergoing AVR is the injurious effects of 
cardiopulmonarybypass to the organs. This results as a systemic inflammatory response and 
this may influence the post-operative course of the elderly patients adversely. 
Paroxysmal or chronic AF and a LVEF <35% is a risk factor for mortality in patients with 
severe AS  undergoing AVR. Of 83 elderly patients with severe AS and an LVEF <35%, 29 
(35%) had paroxysmal or chronic AF (Levy, 2006, as cited in Aronow, 2007). The 
perioperative mortality was 24% in the group with AF versus 5,5% in the group without 
AF. 
11. Transcatheter aortic valve implantation 
Surgical AVR is currently the gold-standard treatment for patients with severe symptomatic 
AS. Without surgery, the prognosis is extremely poor, with a 3-year survival rate of <30%. 
However, in the huge Euro Heart multinational registry in Europe, 33% of symptomatic 
patients over the age of 65 years were not referred for surgery. (Iung et al., 2003). The 
reasons for not planning surgery were not always the co morbidities. David Bach’s series 
showed the same issue and 33% of symptomatic patients were not referred for surgery, 
some of whom had a low Euro Score risk. (Bach et al., 2007). Balloon aortic valvuloplasty, 
which was described in the 1980s, was the first alternative to surgical therapy (Cribier et al., 
1986). Despite high rates of initial procedural success, restenosis is frequently encountered 
in the long term. The procedure has generally been abandoned in adult patients except as a 
palliative procedure often prior to surgical AVR (Eltchaninoff et al., 1995). Trans-catheter 
aortic valve implantation (TAVI) was first described by Andersen et al in 1992 (Andersen et 
al., 1992). They implanted an expandable aortic valve by a catheter technique in a closed 
chest pig model. The first attempt to use TAVI in man was in 2002 by Cribier et al. (Cribier 
et al., 2002). A percutaneous bioprosthesis was successfully implanted within the diseased 
native aortic valve through an antegrade transseptal approach. Percutaneous transcatheter 
implantation of the aortic valve has been utilized as an alternative to open heart surgery in 
high risk patients with symptomatic severe AS who are not suitable for open surgery. 
Patients might be considered candidates for TAVI if they fulfill the following criteria: 
symptomatic severe AS, a life expectancy of >1year, contraindications for surgery, high risk 
for surgery (clinical judgment plus Euro Score (logistic) >20%; STS Score>10%), and/or 
porcelain aorta, history of thoracic irradiation, severe thoracic deformity, patent coronary by 
pass, cachexia, recurrent pulmonary emboli, right ventricular insufficiency and cirrhosis. 
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Stented valves placed either transapically or percutaneously are garnering much attention 
(Lichtenstein et al., 2006; Criber et al., 2006). Within these procedures, firstly balloon aortic 
valvotomy is undertaken and a stented bioprosthesis is then deployed over a balloon into 
the aortic annulus. Inflation of the balloon anchors the valve in place in the annulus, 
effectively achieving AVR. Transapical approach necessitates a thoracotomy but the valve is 
deployed into the beating heart and extracorporeal circulation is not performed. In the 
percutaneous approach, the valve is deployed either antegradely via the transseptal route, 
or retrogradely across the native aortic valve. Contraindications for TAVI are as follows: an 
aortic annulus of <18 mm or >27 mm, bicuspid valves, heavy calcification in front of LM, 
presence of LV thrombus and need for CABG (relative). Some specific contraindications for 
transfemoral approach are; narrow peripheral arteries (diameter < 8-9 mm), severe 
tortuousity or calcification, history of aorto-femoral by pass, aneurysm of abdominal aorta 
with thrombosis, and severe atheroma of the arch. TAVI has revolutionized the 
management of patients with severe AS, with more than 10,000 implants performed to date. 
Two studies corroborated the results of previous reports in a real world population of 
consecutive patients within their respective countries (Eltchaninoff et al., 2010; Zahn et al., 
2011). They demonstrated a technical success rate of 98-99%, similar 30 day mortality rates 
(12%), and an incidence of stroke of 3-4%. A recently published study (Partner Trial) 
successfully met both primary and co-primary endpoints with a significant reduction in 1- 
year mortality (30.7% for TAVI versus 50.7% for standard therapy, p<0.001, Leon et al., 
2010). It also demonstrated there was a significant reduction in the composite endpoint of 
death from any cause or repeat hospitalization (42.5% for TAVI versus 71.6% for standard 
therapy, p<0.0001). However, TAVI as compared with standard therapy, was associated 
with a higher incidence of major strokes (5.0% versus 1.1 %, p=0.06) and major vascular 
complications (16.2% versus 1.1%, p <0.001 Leon et al., 2010). Despite continual technical 
advancement of TAVI devices and procedures, the combined mortality and morbidity is still 
high in the range of 5-10%, especially when we are facing a group of high surgical risk 
patients. In the future when it is a safer and more reliable procedure and further refinement 
of the device (i.e. smaller size delivery systems and multiple valve size options) is done, 
utilization of the procedure in patients with lower surgical risk may be possible. 
12. Geriatric aspects 
12.1 Activities of daily living 
Bemmel et al investigated the impact of valvular heart disease on the activities of daily 
living (ADL, assessed with Groningen Activity Restriction Scale) in eighty one 90-year old 
individuals (Bemmel et al., 2010). The study population consisted of individuals 78% of 
whom lived independently and only 35% had history of cardiovascular disease. Most 
common valve diseases were mitral regurgitation (73%) and aortic regurgitation (47%). AS 
was present in 17% (14 in 81) of the study population (9 mild, 4 moderate and 1 severe). No 
correlation between the presence of valve diseases and dependence in ADL was found in 
this population. It is not feasible to extend these results to the general population because 
the study population consisted of healthier and cognitively more intact individuals expected 
for this age. Because significant AS may cause deterioration in ADL via several mechanisms 
like limitation of functional capacity, depression and cognitive decline due to concomitant 
atherosclerosis in the central nervous system, studies assessing ADL in individuals with 
significant AS are needed. 
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Frailty is a geriatric syndrome which is associated with weakness, instability, limitation, 
increased vulnerability to stressors, and adverse health outcomes like falls, hospitalization, 
institutionalization and mortality (Evans et al., 2010). Although there are various definitions 
to identify individuals with frailty, the most frequently and widely used one was described 
by Fried and colleagues (Fried et al., 2001; Evans et al., 2010). The following five criteria are 
used in this definition: poor grip strength, self-reported exhaustion, unexplained weight 
loss, slow walking speed, and reduced physical activity. An individual having at least three 
of these criteria is defined as being frail. Patients with significant AS might be prone to 
become frail. Self-reported exhaustion, slow walking speed and reduced physical activity 
would be seen in a high percentage of patients with limited physical activity due to 
exertional dyspnea or angina pectoris associated with significant AS. They may also have 
weight loss and poor grip strength associated with cardiac cachexia. Assessment of patients 
with AS about presence of frailty would also be beneficial in perioperative risk assessment 
as stated in section 9.1. Further studies about the impact of frailty on presence, severity and 
perioperative risk of AS are needed. 
12.3 Malnutrition 
Malnutrition is an important health issue in the elderly. Being underweight is associated 
with more frequent all-cause mortality than being overweight in the elderly (Berrington de 
Gonzalez et al., 2010). Undernutrition is also associated with tendency to adverse health 
problems like pressure sores, infections and sarcopenia. 
Data assessing the relationship between heart valve problems and malnutrition are very 
limited. Ikee et al investigated impact of malnutrition-inflammation complex on heart valve 
calcification in 105 patients on hemodialysis (Ikee et al., 2008). In this study mean age was 67 
and aortic (77.4%) and mitral (51.3%) valve calcification rates were very high. They found 
some association between malnutrition and valve calcification. However, as a marker of 
malnutrition they used only albumin level which is not specific for malnutrition. Wang et al 
investigated the association of malnutrition and fetuin-A, which has recently been identified 
as an important circulating inhibitor of calcification, in 238 patients on peritoneal dialysis 
treatment (Wang et al., 2005). Nutritional assessment was done with serum albumin levels 
and subjective global assessment tool in this study. Cardiac valve calcification was present 
in 26% of the patients. They showed a significant correlation between fetuin-A levels and 
presence and degree of malnutrition. Otto et al reported increased long-term mortality 
independently associated with cachexia in 674 elderly patients who underwent balloon 
aortic valvuloplasty for AS (Otto el al., 1994). 
Undernutrition may also influence outcomes after cardiac valve surgery. Tepsuwan et al. 
assessed the incidence and impact of cardiac cachexia retrospectively in 353 patients who 
underwent cardiac valve surgery (Tepsuwan et al., 2009). The study population was 
relatively young and most of them had mitral stenosis or mitral regurgitation. They used the 
finding of a body weight less than 80% of ideal body weight as cachexia which was present 
in 13% of the study population. They found significant association between presence of 
cachexia and worse New York Heart Association functional class, higher incidence of 
infective endocarditis and tricuspid regurgitation, longer postoperative hospitalization and 
more frequent postoperative complications and tendency to a higher mortality rate. 
Thourani et al investigated the impact of body mass index (BMI) on morbidity and mortality 
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after cardiac valve surgery in 4247 patients (Thourani et al., 2011). Most of their study 
population underwent isolated AVR (47.2%) or isolated mitral valve procedure (26%). They 
showed increased in-hospital and all-cause long-term mortality in patients with a BMI of 
less than 25 compared to patients with a BMI of 25-35 or higher than 35. However they had 
no laboratory or clinical data about nutritional status. Engelman et al retrospectively 
assessed impact of BMI and albumin levels on morbidity and mortality after cardiac surgery 
in 5168 patients undergoing coronary artery bypass or valve operations (Engelman et al., 
1999). In their study there was no correlation between albumin levels and BMI. Preoperative 
low albumin (<2.5 g/dl) and low BMI (<20 kg/m2) were independently associated with 
increased postoperative mortality. No nutritional assessment tool was utilized in this study. 
Potentially, significant AS may cause malnutrition via different mechanisms. Dietary 
restriction due to reduced physical capacity and depressive mood may enhance 
malnutrition. Abdominal angina may also cause avoidance from eating when concomitant 
systemic atherosclerosis is present in the mesenteric vessels. Further studies specifically 
investigating the association between malnutrition and AS are needed. 
12.4 Depression 
Depression is the most common psychiatric disorder in the elderly and later-life depression 
(LLD) is associated with disability and increased morbidity and mortality (Maixner et al., 
2011). Because atypical presentations like somatic symptoms are common and LLD is 
generally associated with medical comorbidities, recognition is difficult. Study of Bisschop 
et al., suggested that cardiac disease and arthritis are the most common predisposing factors 
for medical illness related depression (Bischop et al., 2004). Overall medical illness burden 
and degree of functional disability may be more important than specific medical illnesses 
alone (Maixner et al., 2011). Underlying medical illness may affect the prognosis of 
depression and depression may delay recovery from medical illnesses by decreasing 
motivation and compliance (Maixner et al., 2011). The importance of screening for 
depression in patients with heart disease is well established, but identifying patients with 
depression may be difficult because organic somatic symptoms possibly unrelated to mood 
may increase the score on depression ratings and many patients with depression deny a 
depressed mood (Maixner et al., 2011). Nonetheless, many symptoms like insomnia, fatigue, 
shortness of breath, weight loss, palpitations, and exercise intolerance overlap in heart 
disease and depression. Even when patients with depression deny sadness, they endorse 
anhedonia and most other depressive symptoms if further questioning is done (Maixner et 
al., 2011). 
Vascular depression is characterized with late onset or change in course after early onset, 
persistent symptoms, and association of depression with vascular disease or vascular risk 
factors and diffuse or multifocal cerebrovascular lesions (Maixner et al., 2011). Although no 
specific data exist about the association of vascular depression and AS in the elderly, 
atherosclerosis has pivotal role in the pathogenesis of both conditions. 
Among medications possibly precipitating depression are beta blockers, which is being used 
commonly in patients with heart disease. Although there is conflicting data about the 
association of beta blockers and depression, and individual susceptibility to depression may 
be important, patients with risk factors for depression like personal or family history of 
depression should be followed up in terms of development of depression (Verbeek et al., 
2011). Lipophilic beta blockers like propranolol, timolol, pindolol, metoprolol, carvedilol 
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and nebivolol are more strongly associated with depression than hydrophilic beta blockers 
like atenolol, nadolol, practolol and sotalol (Verbeek et al., 2011). It is also important not to 
be reluctant to begin beta blocker treatment when strong indications like CAD exist. 
SSRI are widely used in the treatment of depression. There is some data that indicate use of 
SSRI in patients with CAD and depression may improve cardiovascular outcomes (Kimmel 
et al., 2011). Because both treatment with SSRI and severe AS may reduce platelet functions, 
bleeding complications of surgical procedures may be increased in patients with severe AS 
using SSRI. Because treatment with SSRI may precipitate hyponatremia, monitorization of 
sodium levels is important in patients using SSRI, especially if older age and concomitant 
diuretic use is present. 
13. Conclusion 
Diagnosis and management of AS in the elderly have many differences compared to 
younger patients. Thus, involvement of experienced staff and utilization of comprehensive 
assessment in the management of these patients is crucial. 
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